Gastric Cancer

, Volume 21, Issue 4, pp 703–709 | Cite as

Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications

  • Kojiro Eto
  • Naoki Hiki
  • Koshi Kumagai
  • Yoshiaki Shoji
  • Yasuo Tsuda
  • Yosuke Kano
  • Itaru Yasufuku
  • Yasuhiro Okumura
  • Masahiro Tsujiura
  • Satoshi Ida
  • Souya Nunobe
  • Manabu Ohashi
  • Takeshi Sano
  • Toshiharu Yamaguchi
Original Article

Abstract

Background

The occurrence of postoperative complications may have a significant negative impact on the prognosis of patients with gastrointestinal cancers. The inflammatory response releases systemic cytokines, which may induce residual cancer cell growth. Recently, neoadjuvant chemotherapy (NAC) was found to improve the prognosis of advanced gastric cancer (GC). We hypothesize that when postoperative complications occur after gastrectomy, NAC treatment of micrometastases can prevent residual cancer cell growth.

Methods

This study included 101 patients who underwent curative resection after NAC for GC from 2005 to 2015. Clinical data, including intraoperative parameters, were collected retrospectively. Overall survival (OS) and relapse-free survival (RFS) were compared between the patients with complications and those without complications.

Results

Of the 101 patients, 35 (34.7%) had grade 2 or higher complications. Among those with complications, the 3- and 5-year OS rates were 63.5 and 58.2% and the 3- and 5-year RFS rates 41.7 and 41.7%, respectively. Among those without complications, the 3- and 5-year OS rates were 65.9 and 56.3% and the 3- and 5-year RFS rates 51.1 and 43.9%, respectively. There was no significant difference in prognosis between the patients with complications and those without complications.

Conclusion

Our study is the first to demonstrate the potential of NAC to abolish the poor prognosis induced by postoperative complications after curative resection for GC.

Keywords

Neoadjuvant chemotherapy Gastric cancer Postoperative complication Micrometastases Inflammatory cytokines Prophylactic effect 

Notes

Author contributions

Study conception and design: KE, NH, KK, TS, and TY; acquisition of the data: KE, NH, and KK; analysis and interpretation of the data: KE, NH, and KK; writing of the manuscript: KE, NH, KK, TS, and TY. All authors approved the final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and patient consent

The data collection and analysis were approved by the institutional review board of the Cancer Institute Hospital. Informed consent was obtained from all patients before they were included in this study.

Supplementary material

10120_2017_781_MOESM1_ESM.pptx (87 kb)
Fig. S1 Kaplan–Meier analyses of overall survival (a) and relapse-free survival (b) comparing the low-peak and high-peak CRP groups after resection of GC with curative intent (PPTX 86 kb)

References

  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMedGoogle Scholar
  2. 2.
    Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007;33:315–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Maehara Y, Hasuda S, Koga T, et al. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. Br J Surg. 2000;87:353–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Isobe Y, Nashimoto A, Akazawa K, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011;14:301–16.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gretschel S, Siegel R, Estevez-Schwarz L, et al. Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg. 2006;93:1530–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Walker KG, Bell SW, Rickard MJ, et al. Anastomotic leakage is predictive of diminished survival after potentially curative resection for colorectal cancer. Ann Surg. 2004;240:255–9.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Artinyan A, Orcutt ST, Anaya DA, et al. Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients. Ann Surg. 2015;261:497–505.CrossRefPubMedGoogle Scholar
  8. 8.
    Lerut T, Moons J, Coosemans W, et al. Postoperative complications after transthoracic esophagectomy for cancer of the esophagus and gastroesophageal junction are correlated with early cancer recurrence: role of systematic grading of complications using the modified Clavien classification. Ann Surg. 2009;250:798–807.CrossRefPubMedGoogle Scholar
  9. 9.
    Rizk NP, Bach PB, Schrag D, et al. The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg. 2004;198:42–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Sierzega M, Kolodziejczyk P, Kulig J. Impact of anastomotic leakage on long-term survival after total gastrectomy for carcinoma of the stomach. Br J Surg. 2010;97:1035–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Tokunaga M, Tanizawa Y, Bando E, et al. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575–83.CrossRefPubMedGoogle Scholar
  12. 12.
    Kubota T, Hiki N, Sano T, et al. Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014;21:891–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Saito T, Kurokawa Y, Miyazaki Y, et al. Which is a more reliable indicator of survival after gastric cancer surgery: postoperative complication occurrence or C-reactive protein elevation? J Surg Oncol. 2015;112:894–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Bohle B, Pera M, Pascual M, et al. Postoperative intra-abdominal infection increases angiogenesis and tumor recurrence after surgical excision of colon cancer in mice. Surgery. 2010;147:120–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Eguchi T, Kodera Y, Nakanishi H, et al. The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo. 2008;22:707–12.PubMedGoogle Scholar
  17. 17.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–80.CrossRefPubMedGoogle Scholar
  19. 19.
    Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Tsuburaya A, Nagata N, Cho H, et al. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol. 2013;71:1309–14.CrossRefPubMedGoogle Scholar
  22. 22.
    Kosaka T, Akiyama H, Makino H, et al. Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol. 2014;73:281–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Oki E, Emi Y, Kusumoto T, et al. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer. Ann Surg Oncol. 2014;21:2340–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines (ver 3). Gastric Cancer. 2010;2011(14):113–23.Google Scholar
  25. 25.
    Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41.CrossRefPubMedGoogle Scholar
  27. 27.
    Salvans S, Mayol X, Alonso S, et al. Postoperative peritoneal infection enhances migration and invasion capacities of tumor cells in vitro: an insight into the association between anastomotic leak and recurrence after surgery for colorectal cancer. Ann Surg. 2014;260:939–43.CrossRefPubMedGoogle Scholar
  28. 28.
    Baiocchi GL, Marrelli D, Verlato G, et al. Follow-up after gastrectomy for cancer: an appraisal of the Italian Research Group for Gastric Cancer. Ann Surg Oncol. 2014;21:2005–11.PubMedGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2017

Authors and Affiliations

  • Kojiro Eto
    • 1
  • Naoki Hiki
    • 1
  • Koshi Kumagai
    • 1
  • Yoshiaki Shoji
    • 1
  • Yasuo Tsuda
    • 1
  • Yosuke Kano
    • 1
  • Itaru Yasufuku
    • 1
  • Yasuhiro Okumura
    • 1
  • Masahiro Tsujiura
    • 1
  • Satoshi Ida
    • 1
  • Souya Nunobe
    • 1
  • Manabu Ohashi
    • 1
  • Takeshi Sano
    • 1
  • Toshiharu Yamaguchi
    • 1
  1. 1.Department of Gastroenterological SurgeryCancer Institute HospitalTokyoJapan

Personalised recommendations